EE05212B1 - Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i - Google Patents
Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-iInfo
- Publication number
- EE05212B1 EE05212B1 EEP200200181A EEP200200181A EE05212B1 EE 05212 B1 EE05212 B1 EE 05212B1 EE P200200181 A EEP200200181 A EE P200200181A EE P200200181 A EEP200200181 A EE P200200181A EE 05212 B1 EE05212 B1 EE 05212B1
- Authority
- EE
- Estonia
- Prior art keywords
- preparation
- treatment
- pharmaceutical composition
- tumor cell
- cell expressing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15793399P | 1999-10-06 | 1999-10-06 | |
US18180700P | 2000-02-11 | 2000-02-11 | |
US21568800P | 2000-06-30 | 2000-06-30 | |
PCT/US2000/027579 WO2001024811A1 (en) | 1999-10-06 | 2000-10-05 | April receptor (bcma) and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200200181A EE200200181A (et) | 2003-06-16 |
EE05212B1 true EE05212B1 (et) | 2009-10-15 |
Family
ID=27388102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200181A EE05212B1 (et) | 1999-10-06 | 2000-10-05 | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i |
Country Status (30)
Country | Link |
---|---|
US (1) | US7276241B2 (et) |
EP (3) | EP1223964B1 (et) |
JP (2) | JP4880155B2 (et) |
KR (1) | KR100759295B1 (et) |
CN (1) | CN1263507C (et) |
AT (1) | ATE360434T1 (et) |
AU (1) | AU776852B2 (et) |
BG (1) | BG65473B1 (et) |
BR (1) | BR0014583A (et) |
CA (1) | CA2386463C (et) |
CZ (1) | CZ297633B6 (et) |
DE (1) | DE60034586T2 (et) |
DK (1) | DK1223964T3 (et) |
EA (1) | EA005601B1 (et) |
EE (1) | EE05212B1 (et) |
GE (1) | GEP20043375B (et) |
HK (1) | HK1044710B (et) |
HU (1) | HUP0203567A2 (et) |
IL (3) | IL148839A0 (et) |
IS (1) | IS6322A (et) |
MX (1) | MXPA02003393A (et) |
NO (1) | NO331683B1 (et) |
NZ (1) | NZ517907A (et) |
PL (1) | PL204010B1 (et) |
RS (1) | RS51602B (et) |
SK (1) | SK286331B6 (et) |
TR (1) | TR200200912T2 (et) |
UA (1) | UA74798C2 (et) |
WO (1) | WO2001024811A1 (et) |
ZA (1) | ZA200202578B (et) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541224B2 (en) | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
US7217788B2 (en) | 1996-03-14 | 2007-05-15 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta polypeptides |
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
ATE437947T1 (de) | 1998-06-01 | 2009-08-15 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
US20030095967A1 (en) * | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
US20050100548A1 (en) * | 2001-07-24 | 2005-05-12 | Biogen Idec Ma Inc. | BAFF, inhibitors thereof and their use in the modulation of B-cell response |
DK1210425T4 (en) | 1999-08-17 | 2015-08-10 | Apotech R & D Sa | BAFF receptor (BCMA), an immunoregulatory agent |
PT1255558E (pt) * | 2000-02-16 | 2006-11-30 | Genentech Inc | Anticorpos anti-april e células hibridoma |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US7371388B1 (en) | 2000-05-04 | 2008-05-13 | Human Genome Sciences, Inc. | Treatment of Sjogren's syndrome by administration of TR18 polypeptides |
AU2001261557B2 (en) * | 2000-05-12 | 2005-06-30 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
DE60143798D1 (de) * | 2000-06-16 | 2011-02-17 | Cambridge Antibody Tech | Immunspezifisch bindende antikörper gegen blys |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
WO2002016411A2 (en) | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
AU2002311976A1 (en) | 2001-05-24 | 2002-12-03 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
DE60234202D1 (de) | 2001-05-24 | 2009-12-10 | Zymogenetics Inc | Taci-immunoglobulin-fusionsproteine |
EA200601861A1 (ru) * | 2001-08-03 | 2007-02-27 | Дженентек, Инк. | ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ |
US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
AU2002333502A1 (en) | 2002-02-10 | 2003-09-04 | Apoxis Sa | Fusion constructs containing active sections of tnf ligands |
WO2003072713A2 (en) * | 2002-02-21 | 2003-09-04 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
AU2003256836A1 (en) * | 2002-07-25 | 2004-02-16 | Genentech, Inc. | Taci antibodies and uses thereof |
WO2004094620A2 (en) | 2003-03-28 | 2004-11-04 | Biogen Idec Ma Inc. | Truncated baff receptors |
PL1631313T3 (pl) * | 2003-06-05 | 2015-08-31 | Genentech Inc | Terapia skojarzona zaburzeń z komórek B |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
BRPI0415709A (pt) | 2003-10-20 | 2006-12-19 | Biogen Idec Inc | esquemas terapêuticos para antagonistas de baff |
JP4994224B2 (ja) | 2004-04-22 | 2012-08-08 | アジェンシス,インコーポレイテッド | Steap−1タンパク質に結合する抗体とそれから由来する分子 |
CN1786016B (zh) * | 2004-12-09 | 2010-12-29 | 中国人民解放军军事医学科学院基础医学研究所 | 一种人工构建的生物活性分子及其制备方法 |
EP1836224A1 (en) * | 2004-12-23 | 2007-09-26 | Laboratoires Serono S.A. | Bcma polypeptides and uses thereof |
DE602006007323D1 (de) * | 2005-01-28 | 2009-07-30 | Biogen Idec Inc | VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN |
EP1922079A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
EP1922080A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for treating b-cell malignancies using taci-ig fusion molecule |
NZ568204A (en) | 2005-10-13 | 2012-01-12 | Human Genome Sciences Inc | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
JP2009537563A (ja) | 2006-05-15 | 2009-10-29 | アレス トレーディング ソシエテ アノニム | Taci融合分子を使用する自己免疫疾患を治療するための方法 |
ES2636089T3 (es) | 2006-10-27 | 2017-10-05 | Genentech, Inc. | Anticuerpos e inmunoconjugados y usos para los mismos |
MD36Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare |
MD35Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare |
MD23Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare |
MD24Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare |
WO2011047121A1 (en) * | 2009-10-14 | 2011-04-21 | Schering Corporation | April antagonists and methods of use |
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
WO2013171296A1 (en) | 2012-05-16 | 2013-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic and treatment of sarcoidosis |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3620468A1 (en) | 2013-02-05 | 2020-03-11 | EngMab Sàrl | Method for the selection of antibodies against bcma |
EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
WO2014140243A1 (en) | 2013-03-15 | 2014-09-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction |
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
CA2929774C (en) | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animal cells having a humanized proliferation-inducing ligand gene |
US20170247462A1 (en) | 2014-07-03 | 2017-08-31 | Oklahoma Medical Research Foundation | Treatment of multiple sclerosis and neuromyelitis optica |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
EA036975B1 (ru) | 2015-08-03 | 2021-01-21 | Энгмаб Сарл | Моноклональные антитела против bcma |
EP3337824B1 (en) | 2015-08-17 | 2020-06-03 | Janssen Pharmaceutica NV | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
CA3005042A1 (en) * | 2015-11-13 | 2017-05-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-bcma polypeptides and proteins |
ES2970864T3 (es) | 2015-11-25 | 2024-05-31 | Visterra Inc | Moléculas de anticuerpos contra APRIL y usos de las mismas |
BR112018016697A2 (pt) | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento. |
CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
US11505606B2 (en) | 2016-09-14 | 2022-11-22 | Teneobio, Inc. | CD3 binding antibodies |
WO2018083204A1 (en) | 2016-11-02 | 2018-05-11 | Engmab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
CN110431151B (zh) | 2016-12-21 | 2023-07-18 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
ES2955852T3 (es) | 2017-04-03 | 2023-12-07 | Hoffmann La Roche | Anticuerpos de unión a STEAP-1 |
IL271194B1 (en) | 2017-06-20 | 2024-06-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
MX2019015563A (es) | 2017-06-20 | 2020-07-28 | Teneoone Inc | Anticuerpos anti-bcma unicamente de cadena pesada. |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
MX2020012270A (es) | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. |
CR20200571A (es) | 2018-06-01 | 2021-01-18 | Novartis Ag | Moléculas de únion contra bcma y usos de las mismas |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
EP3983438A1 (en) | 2019-06-14 | 2022-04-20 | TeneoBio, Inc. | Multispecific heavy chain antibodies binding to cd22 and cd3 |
US20220251228A1 (en) | 2019-07-30 | 2022-08-11 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof |
CA3214992A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
US20230203161A1 (en) | 2020-04-29 | 2023-06-29 | Teneobio, Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
US20210379183A1 (en) * | 2020-05-29 | 2021-12-09 | Chinook Therapeutics, Inc. | METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY |
EP4171750A1 (en) | 2020-06-30 | 2023-05-03 | Teneobio, Inc. | Multi-specific antibodies binding to bcma |
CN117279953A (zh) | 2021-02-16 | 2023-12-22 | 詹森药业有限公司 | 靶向bcma、gprc5d和cd3的三特异性抗体 |
JP2024515591A (ja) | 2021-04-08 | 2024-04-10 | マレンゴ・セラピューティクス,インコーポレーテッド | Tcrに結合する多機能性分子およびその使用 |
TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及/或難治性多發性骨髓瘤之治療的方法及組成物 |
CA3228678A1 (en) | 2021-08-11 | 2023-02-16 | Amato J. Giaccia | Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US6218510B1 (en) * | 1994-03-02 | 2001-04-17 | Brigham & Woman's Hospital | B7-1 and B7-2 polypeptides |
US6541224B2 (en) * | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
EP1362916A3 (en) | 1996-03-14 | 2004-02-18 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
ATE302272T1 (de) | 1996-10-25 | 2005-09-15 | Human Genome Sciences Inc | Neutrokin alpha |
AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
CA2292899A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
EP1012292A1 (en) | 1997-06-06 | 2000-06-28 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
EE200000148A (et) * | 1997-09-12 | 2001-02-15 | Biogen, Incorporated | Kay - uus immuunsüsteemi valk |
PL339463A1 (en) * | 1997-09-12 | 2000-12-18 | Biogen | April - novel protein of growth promoting action |
WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
US6297367B1 (en) * | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
AU1467000A (en) | 1998-11-04 | 2000-05-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A novel tumor necrosis factor family member, drl, and related compositions and methods |
GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
EE05460B1 (et) * | 1999-01-07 | 2011-08-15 | Zymogenetics, Inc. | Lahustuv retseptor BR43x2 ja selle kasutamise meetodid |
US20060067933A1 (en) * | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
SI1146892T1 (en) | 1999-01-25 | 2004-02-29 | Biogen, Inc. | Baff, inhibitors thereof and their use in the modulation of the b-cell response |
US6475986B1 (en) * | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
WO2000050597A2 (en) | 1999-02-23 | 2000-08-31 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
JP2002541779A (ja) * | 1999-02-24 | 2002-12-10 | ザ ジュネラル ホスピタル コーポレーション | シグナル伝達中間体のクローニング方法 |
WO2000058362A1 (en) | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
WO2000068378A1 (en) * | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
DK1210425T4 (en) | 1999-08-17 | 2015-08-10 | Apotech R & D Sa | BAFF receptor (BCMA), an immunoregulatory agent |
WO2001058949A2 (en) | 2000-02-11 | 2001-08-16 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
PT1255558E (pt) * | 2000-02-16 | 2006-11-30 | Genentech Inc | Anticorpos anti-april e células hibridoma |
US20040013674A1 (en) | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
AU2001261557B2 (en) | 2000-05-12 | 2005-06-30 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
DE60143798D1 (de) | 2000-06-16 | 2011-02-17 | Cambridge Antibody Tech | Immunspezifisch bindende antikörper gegen blys |
WO2002018620A2 (en) | 2000-08-15 | 2002-03-07 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
WO2003055979A2 (en) | 2001-11-16 | 2003-07-10 | Human Genome Sciences, Inc. | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS |
-
2000
- 2000-05-10 UA UA2002053779A patent/UA74798C2/uk unknown
- 2000-10-05 EE EEP200200181A patent/EE05212B1/et not_active IP Right Cessation
- 2000-10-05 EP EP00968780A patent/EP1223964B1/en not_active Revoked
- 2000-10-05 KR KR1020027004434A patent/KR100759295B1/ko not_active IP Right Cessation
- 2000-10-05 CZ CZ20021169A patent/CZ297633B6/cs not_active IP Right Cessation
- 2000-10-05 RS YU25302A patent/RS51602B/sr unknown
- 2000-10-05 MX MXPA02003393A patent/MXPA02003393A/es active IP Right Grant
- 2000-10-05 PL PL355102A patent/PL204010B1/pl unknown
- 2000-10-05 CA CA2386463A patent/CA2386463C/en not_active Expired - Fee Related
- 2000-10-05 AU AU78645/00A patent/AU776852B2/en not_active Ceased
- 2000-10-05 SK SK451-2002A patent/SK286331B6/sk not_active IP Right Cessation
- 2000-10-05 HU HU0203567A patent/HUP0203567A2/hu unknown
- 2000-10-05 EA EA200200427A patent/EA005601B1/ru unknown
- 2000-10-05 EP EP10181119.8A patent/EP2324844A3/en not_active Withdrawn
- 2000-10-05 BR BR0014583-1A patent/BR0014583A/pt not_active Application Discontinuation
- 2000-10-05 EP EP07106184A patent/EP1847273A1/en not_active Withdrawn
- 2000-10-05 JP JP2001527810A patent/JP4880155B2/ja not_active Expired - Fee Related
- 2000-10-05 TR TR2002/00912T patent/TR200200912T2/xx unknown
- 2000-10-05 GE GE4770A patent/GEP20043375B/en unknown
- 2000-10-05 IL IL14883900A patent/IL148839A0/xx unknown
- 2000-10-05 AT AT00968780T patent/ATE360434T1/de active
- 2000-10-05 NZ NZ517907A patent/NZ517907A/en not_active IP Right Cessation
- 2000-10-05 WO PCT/US2000/027579 patent/WO2001024811A1/en active Application Filing
- 2000-10-05 CN CNB008162557A patent/CN1263507C/zh not_active Expired - Fee Related
- 2000-10-05 DE DE60034586T patent/DE60034586T2/de not_active Expired - Lifetime
- 2000-10-05 DK DK00968780T patent/DK1223964T3/da active
-
2002
- 2002-03-21 IL IL148839A patent/IL148839A/en not_active IP Right Cessation
- 2002-03-22 IS IS6322A patent/IS6322A/is unknown
- 2002-04-02 ZA ZA200202578A patent/ZA200202578B/xx unknown
- 2002-04-02 US US10/115,192 patent/US7276241B2/en not_active Expired - Fee Related
- 2002-04-04 NO NO20021594A patent/NO331683B1/no not_active IP Right Cessation
- 2002-04-30 BG BG106670A patent/BG65473B1/bg unknown
- 2002-08-14 HK HK02105960.3A patent/HK1044710B/zh not_active IP Right Cessation
-
2010
- 2010-03-10 IL IL204401A patent/IL204401A/en not_active IP Right Cessation
-
2011
- 2011-01-07 JP JP2011002461A patent/JP2011079863A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05212B1 (et) | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i | |
IL148089A (en) | Use of anti-bcma antibody to prepare a compound for the treatment of autoimmune disease, a disease associated with B cell proliferation and inflammation | |
PH12012501089A1 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
ATE473243T1 (de) | Humane monoklonale antikörper gegen das kostimulatorische signaltransduktionsmolekül ailim und pharmazeutische verwendungen davon | |
ATE403680T1 (de) | Herstellung tetravalenter antikörper | |
EP1383785A4 (en) | RECOMBINANT, TUMOR-SPECIFIC ANTIBODIES AND THEIR USE | |
ATE123070T1 (de) | Monoklonale antikörper gegen den rezeptor des epidermis-wachstumsfaktors und diese enthaltende therapeutische zubereitungen. | |
IL138424A (en) | Covalently reactive antigen analogs and pharmaceutical compositions containing the same | |
EE200100366A (et) | Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks | |
DE60141297D1 (de) | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper | |
EE05293B1 (et) | RG1 polpeptiidiga seonduv antikeha, seda h?lmav immunkonjugaat ja nende kasutamine | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
DE69821227D1 (de) | Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen | |
BR0012704A (pt) | Anticorpos antitumor, proteìnas e usos dos mesmos | |
FI971879A0 (fi) | Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi | |
FR2798287B1 (fr) | Composition cosmetique riche en nacres, contenant une charge synthetique absorbante | |
AU3553700A (en) | Preparation for the treatment of pigmentation disorders | |
LT97027A (en) | Use of the i-rna in the pharmaceuticals for increasing of the amount of protein encoded by said rna in patient cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change of owner name | ||
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20161005 |